• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by ADC Therapeutics SA

    6/17/25 5:28:58 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADCT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    ADC Therapeutics SA

    (Name of Issuer)


    Common Shares, par value CHF 0.08 per share

    (Title of Class of Securities)


    H0036K147

    (CUSIP Number)


    06/16/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    H0036K147


    1Names of Reporting Persons

    Point72 Asset Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,831,425.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,831,425.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,831,425.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    H0036K147


    1Names of Reporting Persons

    Point72 Capital Advisors, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,831,425.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,831,425.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,831,425.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    H0036K147


    1Names of Reporting Persons

    Steven A. Cohen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,831,425.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,831,425.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,831,425.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ADC Therapeutics SA
    (b)Address of issuer's principal executive offices:

    Biopole, Route De La Corniche 3B, Epalinges, Switzerland, 1066
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the common shares, par value CHF 0.08 per share ("Shares"), of ADC Therapeutics SA (the "Issuer") held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to Shares held by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. Cubist Systematic Strategies, LLC, an advisor under common control with Point72 Asset Management, acts as a sub-advisor with respect to a portion of the Shares reported herein. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902
    (c)Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    (d)Title of class of securities:

    Common Shares, par value CHF 0.08 per share
    (e)CUSIP No.:

    H0036K147
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 16, 2025. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein. The aggregate percentage of the Shares reported to be beneficially owned by each Reporting Person as of June 16, 2025, is based on 112,209,447 Shares outstanding, which is the sum of: (i) 99,178,286 Shares outstanding as of May 1, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 14, 2025, and (ii) 13,031,161 Shares issued upon the closing of a private placement on June 16, 2025, as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on June 12, 2025.
    (b)Percent of class:

    7.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 16, 2025.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 16, 2025.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 16, 2025.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 16, 2025.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Point72 Asset Management, L.P.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:06/17/2025
     
    Point72 Capital Advisors, Inc.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:06/17/2025
     
    Steven A. Cohen
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:06/17/2025
    Exhibit Information

    Exhibit 99.1: Joint Filing Agreement

    Get the next $ADCT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ADCT

    DatePrice TargetRatingAnalyst
    11/8/2024$6.00Overweight
    Stephens
    5/30/2024Overweight
    Cantor Fitzgerald
    3/28/2024$11.00Buy
    Guggenheim
    8/10/2023Underweight → Neutral
    JP Morgan
    4/24/2023$7.00 → $2.00Neutral → Underperform
    BofA Securities
    12/6/2022$12.00Overweight
    CapitalOne
    11/9/2022$14.00 → $7.00Buy → Neutral
    BofA Securities
    9/21/2022$5.00Overweight
    JP Morgan
    More analyst ratings

    $ADCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens initiated coverage on ADC Therapeutics with a new price target

      Stephens initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $6.00

      11/8/24 7:32:36 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on ADC Therapeutics

      Cantor Fitzgerald initiated coverage of ADC Therapeutics with a rating of Overweight

      5/30/24 7:26:04 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on ADC Therapeutics with a new price target

      Guggenheim initiated coverage of ADC Therapeutics with a rating of Buy and set a new price target of $11.00

      3/28/24 7:31:32 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Squarer Ron covered exercise/tax liability with 15,184 shares, decreasing direct ownership by 14% to 93,627 units (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      6/17/25 5:03:44 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sandor Victor covered exercise/tax liability with 12,600 shares, decreasing direct ownership by 10% to 108,286 units (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      6/17/25 5:03:18 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Monges Viviane covered exercise/tax liability with 2,584 shares, decreasing direct ownership by 2% to 144,043 units (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      6/17/25 5:02:50 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

      LAUSANNE, Switzerland, July 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,000 of the Company's common shares to one new employee on July 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate a

      7/1/25 4:05:00 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

      Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69% CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatment ZYNLONTA was generally well tolerated and safety was consistent with known profile LAUSANNE, Switzerland, June 16, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA® to treat relapsed/refractory marginal zone lymphoma (r/r MZL) will be

      6/16/25 7:15:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

      Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

      10/13/22 1:04:01 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

      Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

      10/13/22 1:03:14 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

      Submission status for ADC Therapeutics SA's drug ZYNLONTA (ORIG-1) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 04/23/2021. Application Category: BLA, Application Number: 761196, Application Classification:

      4/23/21 1:46:03 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    SEC Filings

    See more
    • SEC Form S-3 filed by ADC Therapeutics SA

      S-3 - ADC Therapeutics SA (0001771910) (Filer)

      6/30/25 5:28:28 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by ADC Therapeutics SA

      SCHEDULE 13G - ADC Therapeutics SA (0001771910) (Subject)

      6/17/25 5:28:58 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADC Therapeutics SA filed SEC Form 8-K: Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - ADC Therapeutics SA (0001771910) (Filer)

      6/12/25 9:01:23 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Redmile Group, Llc bought $609,000 worth of shares (200,000 units at $3.04) (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      12/13/24 9:00:14 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      7/3/24 8:00:13 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Leadership Updates

    Live Leadership Updates

    See more
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

      £90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi

      7/8/24 2:00:00 AM ET
      $ADCT
      $CG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Investment Managers
      Finance
    • ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

      LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones throughout our hematology and solid tumor portfolios." Th

      6/27/24 7:15:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

      SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

      11/14/24 9:00:57 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

      SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

      11/13/24 8:58:56 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

      SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

      11/13/24 8:30:55 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Financials

    Live finance-specific insights

    See more
    • ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

      ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients 25 of 26 patients achieving CR remained in CR as of the data cut-off Initial data show the combination is generally well tolerated with a manageable safety profile Company expanding enrollment for LOTIS-7 to 100 patients at 150 µg/kg dose Company to host conference call today at 8:00 a.m. ET/2:00 p.m. CEST LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of

      6/12/25 6:30:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

      LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability Forty patient enrollment reached in LOTIS-7 trial dose expansion arm in patients with relapsed/refractory DLBCL Cash runway expected to fund multiple catalysts into the second half of 2026 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (

      5/14/25 8:00:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

      LAUSANNE, Switzerland, May 8, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 8:30 a.m. EDT to report financial results for the first quarter 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event,

      5/8/25 7:15:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care